华讯
/
/
3D Medicines obtains exclusive development and commercialization authorization for new anti-cancer drugs in Greater China

3D Medicines obtains exclusive development and commercialization authorization for new anti-cancer drugs in Greater China

  • 分类:最新消息
  • 作者:华讯知识产权
  • 来源:
  • 发布时间:2020-11-12 16:37
  • 访问量:0

【概要描述】Shanghai, China, November 11, 2020, 3D Medicines announced that it has reached a cooperation with Aravive. 3D Medicines will obtain the exclusive authorization for the clinical development and commercialization of Aravive's new drug AVB-500 in the oncology field of Greater China, and participate in the global clinical trial of AVB-500. Aravive will receive a $12 million contract and will be eligible for development and commercial milestone payments of up to $207 million. In addition, 3 will also pay Aravive a segmented sales commission based on AVB-500's annual net sales in Greater China.



AVB-500, as a specific, high-affinity Fc fusion protein, is a new type of GAS6-AXL signaling pathway inhibitor. The GAS6-AXL signaling pathway is one of the important breakthroughs in the current tumor treatment field, with extremely high clinical value and huge market space. It has been confirmed in pre-clinical studies that AVB-500 can neutralize its activity by binding to GAS6, thereby selectively inhibiting the signaling pathway. At present, the clinical research of the drug is still in progress, and it has obtained fast track qualification granted by the US FDA for platinum-resistant recurrent ovarian cancer indications. In addition, AVB-500 was generally well tolerated, with no dose-limiting toxicity or unexpected safety signals.

Aravive has successfully completed the Phase 1b trial of AVB-500 in platinum-resistant ovarian cancer and will enter the Phase III registration clinical study. Aravive also plans to initiate a Phase 1b/2 clinical trial of AVB-500 in clear cell renal cell carcinoma later in 2020.



The product line of 3D Medicines includes differentiated biomacromolecules and small molecule anticancer drugs, and has an excellent team with international new drug development, registration and commercialization. 3D Medicines CEO Dr. Zhaolong Gong said: “As an innovative drug that can target a variety of tumors, AVB-500, combined with existing standard treatments or the company’s upcoming new drug Envafolimab, is expected to provide more convenient and more convenient Effective treatment options. We will work closely with Aravive to rapidly advance the development and commercialization of AVB-500, and bring this innovative drug with great therapeutic potential to Chinese cancer patients as soon as possible."

3D Medicines obtains exclusive development and commercialization authorization for new anti-cancer drugs in Greater China

【概要描述】Shanghai, China, November 11, 2020, 3D Medicines announced that it has reached a cooperation with Aravive. 3D Medicines will obtain the exclusive authorization for the clinical development and commercialization of Aravive's new drug AVB-500 in the oncology field of Greater China, and participate in the global clinical trial of AVB-500. Aravive will receive a $12 million contract and will be eligible for development and commercial milestone payments of up to $207 million. In addition, 3 will also pay Aravive a segmented sales commission based on AVB-500's annual net sales in Greater China.



AVB-500, as a specific, high-affinity Fc fusion protein, is a new type of GAS6-AXL signaling pathway inhibitor. The GAS6-AXL signaling pathway is one of the important breakthroughs in the current tumor treatment field, with extremely high clinical value and huge market space. It has been confirmed in pre-clinical studies that AVB-500 can neutralize its activity by binding to GAS6, thereby selectively inhibiting the signaling pathway. At present, the clinical research of the drug is still in progress, and it has obtained fast track qualification granted by the US FDA for platinum-resistant recurrent ovarian cancer indications. In addition, AVB-500 was generally well tolerated, with no dose-limiting toxicity or unexpected safety signals.

Aravive has successfully completed the Phase 1b trial of AVB-500 in platinum-resistant ovarian cancer and will enter the Phase III registration clinical study. Aravive also plans to initiate a Phase 1b/2 clinical trial of AVB-500 in clear cell renal cell carcinoma later in 2020.



The product line of 3D Medicines includes differentiated biomacromolecules and small molecule anticancer drugs, and has an excellent team with international new drug development, registration and commercialization. 3D Medicines CEO Dr. Zhaolong Gong said: “As an innovative drug that can target a variety of tumors, AVB-500, combined with existing standard treatments or the company’s upcoming new drug Envafolimab, is expected to provide more convenient and more convenient Effective treatment options. We will work closely with Aravive to rapidly advance the development and commercialization of AVB-500, and bring this innovative drug with great therapeutic potential to Chinese cancer patients as soon as possible."

  • 分类:最新消息
  • 作者:华讯知识产权
  • 来源:
  • 发布时间:2020-11-12 16:37
  • 访问量:0
详情

Shanghai, China, November 11, 2020, 3D Medicines announced that it has reached a cooperation with Aravive. 3D Medicines will obtain the exclusive authorization for the clinical development and commercialization of Aravive's new drug AVB-500 in the oncology field of Greater China, and participate in the global clinical trial of AVB-500. Aravive will receive a $12 million contract and will be eligible for development and commercial milestone payments of up to $207 million. In addition, 3 will also pay Aravive a segmented sales commission based on AVB-500's annual net sales in Greater China.

AVB-500, as a specific, high-affinity Fc fusion protein, is a new type of GAS6-AXL signaling pathway inhibitor. The GAS6-AXL signaling pathway is one of the important breakthroughs in the current tumor treatment field, with extremely high clinical value and huge market space. It has been confirmed in pre-clinical studies that AVB-500 can neutralize its activity by binding to GAS6, thereby selectively inhibiting the signaling pathway. At present, the clinical research of the drug is still in progress, and it has obtained fast track qualification granted by the US FDA for platinum-resistant recurrent ovarian cancer indications. In addition, AVB-500 was generally well tolerated, with no dose-limiting toxicity or unexpected safety signals.

Aravive has successfully completed the Phase 1b trial of AVB-500 in platinum-resistant ovarian cancer and will enter the Phase III registration clinical study. Aravive also plans to initiate a Phase 1b/2 clinical trial of AVB-500 in clear cell renal cell carcinoma later in 2020.

The product line of 3D Medicines includes differentiated biomacromolecules and small molecule anticancer drugs, and has an excellent team with international new drug development, registration and commercialization. 3D Medicines CEO Dr. Zhaolong Gong said: “As an innovative drug that can target a variety of tumors, AVB-500, combined with existing standard treatments or the company’s upcoming new drug Envafolimab, is expected to provide more convenient and more convenient Effective treatment options. We will work closely with Aravive to rapidly advance the development and commercialization of AVB-500, and bring this innovative drug with great therapeutic potential to Chinese cancer patients as soon as possible."

关键词:

扫二维码用手机看

CONTACT

电话:+86 25 56673162 
E-Mail:service@chinaipic.com
地址:江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

公众号二维码

扫一扫,关注我们微博

公众号二维码

扫一扫,关注我们公众号

版权所有 © 南京华讯知识产权顾问有限公司      备案号:苏ICP备15002104号-1      网站建设:中企动力  南京